News | May 14, 2025
Bayer confirms 2025 targets after solid start to the year
EBITDA before special items decreases to €4.08 billion (7.4%)
EBITDA before special items decreases to €4.08 billion (7.4%)
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices
Scores highest PAT of Rs. 118 crore in FY25
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
The FDA issued Form 483 with one observation related to building and facility management
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
Subscribe To Our Newsletter & Stay Updated
